NRl 568/l NR568l Midterml Exam:l
Advancedl Pharmacologyl forl thel
AGPCNPl Guidel (Latestl 2026/l 2027l
Update)l |l Qsl &l As|l Gradel A|l 100%l
Correctl (Verifiedl Answers)-l Chamberlain
QUESTION
classesl ofl antibiotics
Answer:
Penicillins
Cephalosporins
Tetracyclines
Macrolides
Aminoglycosides
Fluoroquinolones
Sulfonamides
QUESTION
Penicillinsl model ofl actionl andl pharmacokinetics
Answer:
-inhibitionl ofl peptidoglycanl celll walll synthesis
-welll absorbedl inl GI,l smalll amountl isl metabolizedl butl mostl isl excretedl unchangedl inl
urine
QUESTION
Penicillinl Monitoring
Answer:
,Renall impairmentl becausel itl canl accumulatel ifl thel kidneyl isl notl workingl thatl couldl
causel toxicl levels.
QUESTION
Penicillinl highl riskl patients
Answer:
historyl ofl severel allergicl reactionsl tol penicillin,l cephalosporinl orl carbapenems
QUESTION
Penicillinl evalutationl ofl therapeuticl effects
Answer:
reductionl ofl symptomsl likel fever,l edema,l painl andl inflammation
QUESTION
Cephalosporinl therapeuticl goal
Answer:
treatmentl ofl infectionl thatl isl causedl byl susceptiblel organism
QUESTION
Cephalosporinl baselinel data
Answer:
Takel samplesl forl culturel tol identifyl thel infectingl organism
QUESTION
Cephl Monitoring
Answer:
Nonel .l Nol routinel labl monitroingl isl suggested.
,QUESTION
Cephl highl riskl patients
Answer:
historyl ofl allergicl reactionsl tol ceph,l pcnl andl carbapenem
QUESTION
Cephl evaluationl ofl therapy
Answer:
reductionl ofl symptomsl likel fever,l pain,l edemal andl inflammation
QUESTION
Cephl miniminizel adversel effects
Answer:
Becausel itl canl promotel C-diffl instructl patientsl tol reportl increasel inl stooll frequency.
QUESTION
Carbapenemsl baseline
Answer:
takel samplel forl culturel tol determinel infectingl organism
QUESTION
Carbapenemsl monitoing
Answer:
None.l Nothingl isl recommended.
QUESTION
, Carbapenemsl highl riskl patients
Answer:
historyl ofl allergicl reaction
patientl usingl valprotatel tol controll seizurel shouldl neverl bel givenl imipenem
QUESTION
Carbapenemsl evaluation
Answer:
decreasel onl symptomsl likel fever,l pain,l edemal andl inflammation
QUESTION
Carbapenemsl minimizel adversel effects
Answer:
dosagel shouldl bel reducedl forl patientsl withl renall impairmentl tol preventl toxicity
QUESTION
Vancomycinl therapeuticl goal
Answer:
Treatmentl ofl seriousl infections,l includingl C-diff,l MRSA,l andl infectionsl thatl arel causedl
byl susceptiblel organismsl inl patientsl allergicl tol PCN.
QUESTION
Vancol baseline
Answer:
culturel andl sensitivity
QUESTION
Vancol monitoring
Advancedl Pharmacologyl forl thel
AGPCNPl Guidel (Latestl 2026/l 2027l
Update)l |l Qsl &l As|l Gradel A|l 100%l
Correctl (Verifiedl Answers)-l Chamberlain
QUESTION
classesl ofl antibiotics
Answer:
Penicillins
Cephalosporins
Tetracyclines
Macrolides
Aminoglycosides
Fluoroquinolones
Sulfonamides
QUESTION
Penicillinsl model ofl actionl andl pharmacokinetics
Answer:
-inhibitionl ofl peptidoglycanl celll walll synthesis
-welll absorbedl inl GI,l smalll amountl isl metabolizedl butl mostl isl excretedl unchangedl inl
urine
QUESTION
Penicillinl Monitoring
Answer:
,Renall impairmentl becausel itl canl accumulatel ifl thel kidneyl isl notl workingl thatl couldl
causel toxicl levels.
QUESTION
Penicillinl highl riskl patients
Answer:
historyl ofl severel allergicl reactionsl tol penicillin,l cephalosporinl orl carbapenems
QUESTION
Penicillinl evalutationl ofl therapeuticl effects
Answer:
reductionl ofl symptomsl likel fever,l edema,l painl andl inflammation
QUESTION
Cephalosporinl therapeuticl goal
Answer:
treatmentl ofl infectionl thatl isl causedl byl susceptiblel organism
QUESTION
Cephalosporinl baselinel data
Answer:
Takel samplesl forl culturel tol identifyl thel infectingl organism
QUESTION
Cephl Monitoring
Answer:
Nonel .l Nol routinel labl monitroingl isl suggested.
,QUESTION
Cephl highl riskl patients
Answer:
historyl ofl allergicl reactionsl tol ceph,l pcnl andl carbapenem
QUESTION
Cephl evaluationl ofl therapy
Answer:
reductionl ofl symptomsl likel fever,l pain,l edemal andl inflammation
QUESTION
Cephl miniminizel adversel effects
Answer:
Becausel itl canl promotel C-diffl instructl patientsl tol reportl increasel inl stooll frequency.
QUESTION
Carbapenemsl baseline
Answer:
takel samplel forl culturel tol determinel infectingl organism
QUESTION
Carbapenemsl monitoing
Answer:
None.l Nothingl isl recommended.
QUESTION
, Carbapenemsl highl riskl patients
Answer:
historyl ofl allergicl reaction
patientl usingl valprotatel tol controll seizurel shouldl neverl bel givenl imipenem
QUESTION
Carbapenemsl evaluation
Answer:
decreasel onl symptomsl likel fever,l pain,l edemal andl inflammation
QUESTION
Carbapenemsl minimizel adversel effects
Answer:
dosagel shouldl bel reducedl forl patientsl withl renall impairmentl tol preventl toxicity
QUESTION
Vancomycinl therapeuticl goal
Answer:
Treatmentl ofl seriousl infections,l includingl C-diff,l MRSA,l andl infectionsl thatl arel causedl
byl susceptiblel organismsl inl patientsl allergicl tol PCN.
QUESTION
Vancol baseline
Answer:
culturel andl sensitivity
QUESTION
Vancol monitoring
